Vertex Pharmaceuticals (NASDAQ: VRTX) revenue
Vertex Pharmaceuticals reported revenue of $12,001m for fiscal 2025, 8.9% more than in fiscal 2024 ($11,020m). Since fiscal 2016 its revenue has grown by 605.1%, an average growth of 24.2% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $12,001m | +8.9% | $4,173m | 34.8% |
| 2024 | $11,020m | +11.7% | −$232.9m | −2.1% |
| 2023 | $9,869m | +10.5% | $3,832m | 38.8% |
| 2022 | $8,931m | +17.9% | $4,307m | 48.2% |
| 2021 | $7,574m | +22.1% | $2,782m | 36.7% |
| 2020 | $6,206m | +49.1% | $2,856m | 46.0% |
| 2019 | $4,163m | +36.6% | $1,198m | 28.8% |
| 2018 | $3,048m | +22.5% | $635.2m | 20.8% |
| 2017 | $2,489m | +46.2% | $123.2m | 5.0% |
| 2016 | $1,702m | — | $9.9m | 0.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Vertex Pharmaceuticals
- How much revenue did Vertex Pharmaceuticals make in fiscal 2025?
- Vertex Pharmaceuticals reported revenue of $12,001m for fiscal 2025, compared with $11,020m in fiscal 2024.
- How much has the revenue of Vertex Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $1,702m to $12,001m: 605.1% more, an average growth of 24.2% a year.
- What was the best year for revenue at Vertex Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $12,001m.
- Where do the figures for Vertex Pharmaceuticals come from?
- From the annual report (Form 10-K) that Vertex Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Vertex Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Vertex Pharmaceuticals: the Vertex Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.